Journal of Oncological Science

Journal of Oncological Science

Volume 1, January 2016, Pages 13-16
Journal of Oncological Science

Review
Pathogenesis of bone metastasis

https://doi.org/10.1016/j.jons.2015.11.004Get rights and content
Under a Creative Commons license
open access

Abstract

Bone metastases are more frequently seen as a complication of cancer than primary bone tumors. For example, it can be seen in as many as 70% of advanced stage breast and prostate cancer cases. Metastatic bone disease is generally categorized as osteoblastic, and osteolytic disease. However most of the cancer types demonstrate a wide spectrum between these two extremes. Paracrine interaction between parathyroid hormone–related protein (PTHrP) which increases the rate of bone osteolysis, and transforming growth factor-β (TGF-β) plays a role in osteolytic metastasis. Increased local bone PTHrP concentration increases expression of receptor activator of nuclear factor kappa-B ligand (RANKL) with resultant activation of osteoclastogenesis. Endothelin – 1 (ET-1), and dickkopf homolog -1 (DKK-1) produced by tumor involve in osteoblastic metastasis. DKK-1 is the central regulator of osteoblastic activity, and osteoblastic bone metastasis. For the elaboration of treatment strategies against frequently seen complication, that is, bone metastases, targets involving in pathogenesis of these complications should be taken into consideration.

Keywords

Bone metastasis
Cancer
Osteoblast
Osteoclast

Cited by (0)

Peer review under responsibility of Turkish Society of Medical Oncology.